Organon & Co. (NYSE:OGN) Hits New 12-Month Low – Here’s What Happened

Shares of Organon & Co. (NYSE:OGN) reached a new 52-week low on Monday . The company traded as low as $5.76 and last traded at $5.7650, with a volume of 620674 shares. The stock had previously closed at $5.84.

Analyst Upgrades and Downgrades

OGN has been the topic of several recent research reports. Zacks Research cut Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Wall Street Zen cut Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Finally, Barclays upped their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $8.50.

Organon & Co. Price Performance

The company has a debt-to-equity ratio of 11.47, a quick ratio of 1.23 and a current ratio of 1.82. The firm has a market capitalization of $1.49 billion, a P/E ratio of 8.02, a price-to-earnings-growth ratio of 0.54 and a beta of 0.60. The company has a 50-day moving average price of $7.47 and a 200-day moving average price of $8.01.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The company had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter in the prior year, the company posted $0.90 EPS. The company’s revenue for the quarter was down 5.3% compared to the same quarter last year. On average, sell-side analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend was Monday, February 23rd. Organon & Co.’s dividend payout ratio (DPR) is currently 11.27%.

Institutional Trading of Organon & Co.

A number of large investors have recently made changes to their positions in OGN. AQR Capital Management LLC grew its position in shares of Organon & Co. by 105.2% in the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares during the period. Vanguard Group Inc. raised its holdings in Organon & Co. by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after buying an additional 3,650,860 shares during the period. Norges Bank bought a new position in Organon & Co. in the second quarter valued at approximately $19,778,000. UBS Group AG boosted its holdings in shares of Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after buying an additional 1,527,492 shares during the period. Finally, Private Management Group Inc. boosted its holdings in shares of Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after buying an additional 1,204,979 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.